Cancer is one of the most fatal diseases of recent times that causes several deaths every
year. The disease variations in different parts of the world, the impact of available medical …

Background Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …

Lung cancer remains one of the major human malignancies affecting both men and women
worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent type. Multiple …

Introduction The phase 3 PACIFIC trial established consolidation therapy with durvalumab
as standard of care for patients with unresectable, stage III NSCLC and no disease …

Introduction On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461),
durvalumab is standard of care for patients with stage III, unresectable NSCLC and no …

Background Osimertinib is a recommended treatment for advanced non–small-cell lung
cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant …

Epidermal growth factor receptor (EGFR) mutations are detected in up to one third of
patients with unresectable stage III non-small cell lung cancer (NSCLC). The current …

Background Operable stage I-III non-small cell lung cancer (NSCLC) has a high risk of
recurrence, mainly due to remnant clones of the disease defined as minimal residual …

Purpose To develop a radiation therapy summary of recommendations on the management
of locally advanced non-small cell lung cancer (NSCLC) based on the Management of …

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality
worldwide. Despite advances in treatment, the prognosis remains poor, highlighting the …